in vitro News and Research

RSS

Study provides new insight into how pyrazinamide works

Pyrazinamide (PZA)-a frontline tuberculosis drug-kills dormant persister bacteria and plays a critical role in shortening TB therapy. PZA is used for treating both drug susceptible and multi-drug resistant TB but resistance to PZA occurs frequently and can compromise treatment.

14 Jun 2013

Solution-based circuit chip for rapid, multiplexed detection of pathogens

Life-threatening bacterial infections cause tens of thousands of deaths every year in North America. Increasingly, many infections are resistant to first-line antibiotics. Unfortunately, current methods of culturing bacteria in the lab can take days to report the specific source of the infection, and even longer to pinpoint the right antibiotic that will clear the infection.

13 Jun 2013

Whitehead Institute researchers identify drug target for anemia

Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.

10 Jun 2013

Novel abnormalities in FGFR gene identified in a spectrum of cancers

Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

10 Jun 2013

BioFire Diagnostics' FilmArray Blood Culture Identification Panel receives CE IVD Mark

BioFire Diagnostics, Inc. announced today that it obtained the CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices for its FilmArray Blood Culture Identification Panel.

6 Jun 2013

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.

6 Jun 2013

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

A research team led by the Duke-NUS Graduate Medical School in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia, making it possible to develop drugs that may extend the survival of these patients.

4 Jun 2013

Arcturus Therapeutics closes $1.3 M in seed funding round

Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada.

3 Jun 2013

Research suggests medullary thymic epithelial cells may have evolved from cortical-thymic TECs

Medullary thymic epithelial cells (mTECs) allow the thymus to ensure that the body's T cells are able to distinguish between potentially harmful foreign antigens and those that are produced by the body itself.

3 Jun 2013

Euro-Peristat project releases second European Perinatal Health Report

The European Perinatal Health Report released by the Euro-Peristat project is the most comprehensive report on the health and care of pregnant women and babies in Europe and brings together data from 2010 from 26 European Union member states, plus Iceland, Norway and Switzerland.

1 Jun 2013

New nanoparticle gene delivery method to prevent stenting procedure complications

Stent angioplasty saves lives, but there often are side effects and complications related to the procedure, such as arterial restenosis and thrombosis. In the June 2013 issue of The FASEB Journal, however, scientists report that they have discovered a new nanoparticle gene delivery method that may overcome current limitations of gene therapy vectors and prevent complications associated with the stenting procedure.

1 Jun 2013

Novel approach to create unlimited number of human red blood cells, platelets in vitro

A study led by Boston University School of Medicine has identified a novel approach to create an unlimited number of human red blood cells and platelets in vitro. In collaboration with Boston University School of Public Health and Boston Medical Center, the researchers differentiated induced pluripotent stem cells into these cell types, which are typically obtained through blood donations.

31 May 2013

Viewpoints: Medical professionals and near misses; Two tea partiers diverge on Medicaid expansion; Obamacare's 'death by a thousand cuts'

A near miss, like any error, is an opportunity to examine how mistakes are made and what changes might prevent them. Yet we have no idea how many near misses there are. Many experts feel that near-miss errors dwarf the number of known errors, a number that is already too high for comfort. (According to a 2006 report, medication errors alone injure an estimated 1.5 million patients a year.) But the instinct for most medical professionals is to keep these shameful mistakes to ourselves (Danielle Ofri, 5/28).

30 May 2013

Researchers codify age-specific probabilities of live birth after IVF with frozen eggs

Researchers from New York Medical College and the University of California Davis have for the first time codified age-specific probabilities of live birth after in vitro fertilization (IVF) with frozen eggs.

30 May 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Frutarom Health, Switzerland, reports increased demand for Go-Less, its natural ingredient targeting urinary incontinence in adults.

28 May 2013

Lab-based skin test eliminates risk of adverse reactions to new drugs, cosmetics

A simple lab-based skin test which eliminates the risk of adverse reactions to new drugs, cosmetics and household chemicals has been developed by a Newcastle University, UK team.

28 May 2013

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection.

24 May 2013

FDA approves Tina-quant HbA1cDx assay for diagnosis of diabetes

Today the U.S. Food and Drug Administration announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabetes by health care professionals.

24 May 2013

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects.

23 May 2013

in vitro News and Research

Study provides new insight into how pyrazinamide works

Solution-based circuit chip for rapid, multiplexed detection of pathogens

Whitehead Institute researchers identify drug target for anemia

Novel abnormalities in FGFR gene identified in a spectrum of cancers

BioFire Diagnostics' FilmArray Blood Culture Identification Panel receives CE IVD Mark

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

Arcturus Therapeutics closes $1.3 M in seed funding round

Research suggests medullary thymic epithelial cells may have evolved from cortical-thymic TECs

Euro-Peristat project releases second European Perinatal Health Report

New nanoparticle gene delivery method to prevent stenting procedure complications

Novel approach to create unlimited number of human red blood cells, platelets in vitro

Viewpoints: Medical professionals and near misses; Two tea partiers diverge on Medicaid expansion; Obamacare's 'death by a thousand cuts'

Researchers codify age-specific probabilities of live birth after IVF with frozen eggs

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Frutarom reports increased demand for natural ingredient targeting urinary incontinence in adults

Lab-based skin test eliminates risk of adverse reactions to new drugs, cosmetics

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

FDA approves Tina-quant HbA1cDx assay for diagnosis of diabetes

University of Granada researchers patent new treatment for acne

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News